# Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/pembrolizumab-versus-investigator-choice-chemotherapy-for-metastatic-triple/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Eric P. Winer,Oleg Lipatov,Seock‐Ah Im,Anthony Gonçalvès,Eva Muñoz‐Couselo,Keun Seok Lee,Peter Schmid,Kenji Tamura,Laura Testa,Isabell Witzel,Shoichiro Ohtani,Nicholas C. Turner,Stefania Zambelli,Nadia Harbeck,Fabrice André,Rebecca Dent,Xuan Zhou,Vassiliki Karantza,Jaime Mejia,Javier Cortés |
| Citations | 499 |
| DOI | 10.1016/s1470-2045(20)30754-3 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3135755572 |
| PMID | 33676601 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Jaime Mejia](https://scholariq.org/researchers/jaime-mejia/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.